MUMBAI Biocon(BION.NS), India's top listed biotech firm, plans to launch psoriasis drug Alzumab in the country in the July-September quarter, a top company executive said on Friday.
The company expects sales of 1 billion rupees from the drug over four years, Kiran Mazumdar-Shaw, chairman, Biocon said in a conference call.
Late on Thursday, Biocon reported an 8.24 percent rise in net profit to 920 million rupees for the Oct-Dec quarter compared with a year earlier.
(Reporting by Kaustubh Kulkarni; Editing by Prateek Chatterjee)
Trending On Reuters
The Reserve Bank of India (RBI) kept its key repo lending rate unchanged at 6.75 percent on Tuesday, as widely expected, after consumer inflation picked up to a four-month high and as emerging markets brace for a U.S. rate hike. Full Article